In our studies, high ALKBH5 expression was associated with clinical features such as IDH wildtype status, 1p/19q non-codeleted status, and demethylation of MGMT, all of which were related to poor prognosis in the glioma patients. The gene discussed is IDH1; the disease is central nervous system cancer.